We believe that constant research and innovation is crucial for the patient’s health care.

Together with our network of international partners, we consider it essential to fully investigate cannabis-based medicine in order to understand their mode of action. Based on this research, we are constantly improving our product-portfolio and developing new preparations made from the cannabis plant. We have the ambition to provide patients, with the best possible cannabinoid-treatment and provide physicians and pharmacists with education about the cannabis-plant.

Our International Network of R&D partners

Connect 4

Connect 4 is founding partner of CanPharma and is extending our expertise, when it comes to questions regarding market access for pharmaceuticals and medical devices. Among others Connect 4 has years of experiences in the fields of regulatory affairs, market intelligence, market entry and market penetration. Together with the Connect 4 team, we are expanding the variety of products on the market with new, great cannabis-based pharmaceuticals.

CBM Labs

Together with CBM Labs, we are focusing on the bio-synthetic production of cannabinoids. CBM Labs is based in the Netherlands and already filed in several patents in order to develop formulations based on cannabinoids. Furthermore, CanPharma will provide CBM Labs with cannabis-based pharmaceuticals for research purposes and CBM Labs will support CanPharma to improve the quality of its product varieties to ensure patient-oriented medicine.

Do you have any questions?

Logo Can Pharma SVG

CanPharma has a pharmaceutical wholesale permission according to §52a of the German Medicines Act, as well as a license to handle narcotics in the meaning of §3 of the German narcotics legislation. Furthermore, CanPharma has a GDP-certified quality assurance system.



CanPharma GmbH
Wiesbadener Str. 29
16515 Oranienburg, Germany


Rosenthaler Str. 34
10178 Berlin

Gran de Gràcia 15, 1-1
08012 Barcelona